Cardiovascular Outcomes With Glp-1 Receptor Agonists In Type 2 Diabetes

Cardiovascular Outcomes With GLP-1 Receptor Agonists in Type 2 Diabetes

GLP-1 Agonists in T2D: Cardiovascular Outcomes Data

GLP-1 Agonists: CV Outcomes Data in Type 2 Diabetes

Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists

Harvard Medical School Continuing Education

GLP-1 Receptor Agonists and Cardiovascular Benefit

Using GLP1 receptor agonists to treat cardiac patients with diabetes

Ted Rogers Centre for Heart Research

GLP-1 Receptor Agonists: Initial Cardiovascular Evidence

Cardiovascular and Renal Outcomes in Type 2 Diabetes Medications with Dr. Marie McDonnell

Optimizing Cardiovascular Outcomes in Type 2 Diabetes: Beyond A1C Goals

The use of GLP-1 receptor agonists for reducing cardiovascular risk on type-2 diabetes patients

Xpeer Medical Education

Cardiovascular Disease Burden in Type 2 Diabetes: Strategies to Improve Outcomes

Semaglutide and Cardiovascular Outcomes in Obesity | NEJM

Protocols for Safe Use of SGLT2i and GLP1RA in the Hospital Setting

University of Ottawa Heart Institute

Exploring the Science and Practice of GLP-1 Receptor Agonists

SGLT2 Inhibitors and GLP1 Receptor Agonists Reduce All-Cause Mortality Among Other Patient Benefits

Family & Community Medicine Grand Rounds

Cardiovascular Outcomes in Patients with Diabetes

Cardiovascular Outcomes Trials With Anti-Diabetes Medications

Optimizing Cardiovascular, Renal Prognosis in Diabetes with GLP-1, SGLT2 Combination

Cardiac & Renal Outcomes with Efpeglenatide in Diabetes (AMPLITUDE-O) | NEJM | Med Journal Club

Med Journal Club

GLP1 RA and Cardiovascular Outcome Trials | IDEC2021